This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Huang, Y.-W. Articles by Lin, S.-X. Search for Related Content PubMed PubMed Citation Articles by Huang, Y.-W. Articles by Lin, S.-X.

Critical Residues for the Specificity of Cofactors and Substrates in Human Estrogenic 17ß-Hydroxysteroid Dehydrogenase 1: Variants Designed from the Three-Dimensional Structure of the Enzyme

Medical Research Council Group in Molecular Endocrinology, Oncology, and Molecular Endocrinology Research Center, Laval University Medical Center, Québec, Québec G1V 4G2, Canada

Address all correspondence and requests for reprints to: Sheng-Xiang Lin, Medical Research Council Group in Molecular Endocrinology, Oncology, and Molecular Endocrinology Research Center, Laval University Medical Center, 2705 Boulevard Laurier, Québec, Québec G1V 4G2, Canada. E-mail: sxlin{at}crchul.ulaval.ca

Human estrogenic 17ß-hydroxysteroid dehydrogenase is an NADP(H)-preferring enzyme. It possesses 11- and 4-fold higher specificity toward NADP(H) over NAD(H) for oxidation and reduction, respectively, as demonstrated by kinetic studies. To elucidate the roles of the amino acids involved in cofactor specificity, we generated variants by site-directed mutagenesis. The results showed that introducing a positively charged residue, lysine, at the Ser12 position increased the enzyme’s preference for NADP(H) more than 20-fold. Substitution of the negatively charged residue, aspartic acid, into the Leu36 position switched the enzyme’s cofactor preference from NADPH to NAD with a 220-fold change in the ratio of the specificity toward the two cofactors in the case of oxidation. This variant dramatically abolished the enzyme’s reductase function and stimulated its dehydrogenase activity, as shown by enzyme activity in intact cells. The substrate-binding pocket was also studied with four variants: Ser142Gly, Ser142Cys, His221Ala, and Glu282Ala. The Ser142Gly variant abolished most of the enzyme’s oxidation and reduction activities. The residual reductase activity in vitro is less than 2% that of the wild-type enzyme. However, the Ser142Cys variant was fully inactive, both as a partially purified protein and in intact cells. This suggests that the bulky sulfhydryl group of cysteine entirely disrupted the catalytic triad and that the Ser142 side chain is important for maintaining the integrity of this triad. His221 variation weakened the apparent affinity for estrone, as demonstrated by a 30-fold increase in Michaelis-Menten constant, supporting its important role in substrate binding. This residue may play an important role in substrate inhibition via the formation of a dead-end complex. The formerly suggested importance of Glu282 could not be confirmed.

This article has been cited by other articles:

				D. P. Sherbet, O. L. Guryev, M. Papari-Zareei, D. Mizrachi, S. Rambally, S. Akbar, and R. J. Auchus Biochemical Factors Governing the Steady-State Estrone/Estradiol Ratios Catalyzed by Human 17{beta}-Hydroxysteroid Dehydrogenases Types 1 and 2 in HEK-293 Cells Endocrinology, September 1, 2009; 150(9): 4154 - 4162. [Abstract] [Full Text] [PDF]

				A. Rahier, M. Bergdoll, G. Genot, F. Bouvier, and B. Camara Homology Modeling and Site-Directed Mutagenesis Reveal Catalytic Key Amino Acids of 3{beta}-Hydroxysteroid-Dehydrogenase/C4-Decarboxylase from Arabidopsis Plant Physiology, April 1, 2009; 149(4): 1872 - 1886. [Abstract] [Full Text] [PDF]

				J. M Day, H. J Tutill, A. Purohit, and M. J Reed Design and validation of specific inhibitors of 17{beta}-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis Endocr. Relat. Cancer, September 1, 2008; 15(3): 665 - 692. [Abstract] [Full Text] [PDF]

				R. Geissler, W. Brandt, and J. Ziegler Molecular Modeling and Site-Directed Mutagenesis Reveal the Benzylisoquinoline Binding Site of the Short-Chain Dehydrogenase/Reductase Salutaridine Reductase Plant Physiology, April 1, 2007; 143(4): 1493 - 1503. [Abstract] [Full Text] [PDF]

				M. Papari-Zareei, A. Brandmaier, and R. J. Auchus Arginine 276 Controls the Directional Preference of AKR1C9 (Rat Liver 3{alpha}-Hydroxysteroid Dehydrogenase) in Human Embryonic Kidney 293 Cells Endocrinology, April 1, 2006; 147(4): 1591 - 1597. [Abstract] [Full Text] [PDF]

				L Y Zhou, D S Wang, B Senthilkumaran, M Yoshikuni, Y Shibata, T Kobayashi, C C Sudhakumari, and Y Nagahama Cloning, expression and characterization of three types of 17{beta}-hydroxysteroid dehydrogenases from the Nile tilapia, Oreochromis niloticus J. Mol. Endocrinol., August 1, 2005; 35(1): 103 - 116. [Abstract] [Full Text] [PDF]

				A. K. Agarwal and R. J. Auchus Minireview: Cellular Redox State Regulates Hydroxysteroid Dehydrogenase Activity and Intracellular Hormone Potency Endocrinology, June 1, 2005; 146(6): 2531 - 2538. [Abstract] [Full Text] [PDF]

				S. Watanabe, T. Kodaki, and K. Makino Complete Reversal of Coenzyme Specificity of Xylitol Dehydrogenase and Increase of Thermostability by the Introduction of Structural Zinc J. Biol. Chem., March 18, 2005; 280(11): 10340 - 10349. [Abstract] [Full Text] [PDF]

				J. L. Thomas, W. L. Duax, A. Addlagatta, S. Brandt, R. R. Fuller, and W. Norris Structure/Function Relationships Responsible for Coenzyme Specificity and the Isomerase Activity of Human Type 1 3{beta}-Hydroxysteroid Dehydrogenase/Isomerase J. Biol. Chem., September 12, 2003; 278(37): 35483 - 35490. [Abstract] [Full Text] [PDF]